Project Grant R01HL174609
Award Date
6/1/25
Completion Date
3/31/29
Dollars Obligated
$737K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Milwaukee, WI 53226, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,276,908 to Bloodworks, a nonprofit organization in Seattle, to conduct advanced molecular and translational research on hematologic disorders. The key focus areas of the research are von Willebrand disease and sickle cell disease, both of which involve the von Willebrand factor (VWF). The studies aim to investigate the impact...
The federal Project Grant award R01HL176322, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Program (CFDA 93.837), supports research to define lipoprotein(a) (Lp(a)) risk thresholds, explore mechanisms for Lp(a)-associated heightened atherosclerotic cardiovascular disease (ASCVD) risk, and study regulation of hepatic Lp(a) production in people with HIV (PWH). The $1,485,606 award, with a performance period from Sep 1, 2024 to Aug...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $2,508,741 to investigate the functional interactions between lipoproteins and protease inhibitors in atherosclerosis. The research aims to: 1) examine the structural and functional interactions between lipoproteins, such as LDL and HDL, and the protease inhibitor alpha-1-antitrypsin (AAT); 2) determine the role of...
This Project Grant award of $151,523 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of fibrinogen in regulating thromboinflammation in acute and chronic venous thrombosis. The principal investigator will use novel RNA therapy, delivered via lipid nanoparticles, to selectively reduce circulating fibrinogen levels in rodent and swine models of thrombosis. The goal is to provide...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $787,267 to Yale University from January 1, 2025 to November 30, 2028. The project aims to determine whether genetic deletion or pharmacological inhibition of the DHCR24 enzyme in macrophages and hepatocytes can increase desmosterol levels, reduce vascular inflammation, and protect against the progression of atherosclerosis. The...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $2,000,032 to Yale University to investigate a novel mechanism for polyunsaturated fatty acid uptake and action in neutrophils. The research aims to determine how the protein LRP5 transports these fatty acids and how this process regulates neutrophil activities and inflammatory diseases, including myocardial ischemia-reperfusion injury....
This federal Project Grant award, with ID R01HL179813, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The $700,338 award supports research to improve understanding of the molecular mechanisms by which the protein complex "retriever" regulates cholesterol homeostasis through the recycling of LDL receptors. The research team at the University of Texas Southwestern Medical Center will...
The University of North Carolina at Chapel Hill received a $1,602,792 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837). The grant, effective January 15, 2025 through November 30, 2028, supports research to examine the phenotypic consequences of lipoprotein(a) [Lp(a)] in diverse global populations. The research aims to identify and characterize both anticipated and unanticipated effects of...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $395,314 to The Leland Stanford Junior University to define the innate immune cell profile that mediates the development of inhibitory antibodies against infused coagulation factor VIII in persons with hemophilia A. The central goal is to advance understanding of the early immunological events that lead to factor VIII immunity,...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), awarded a $2,181,177 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of California, Los Angeles (UCLA) for the project "MECHANISMS OF NONVESICULAR CHOLESTEROL TRANSPORT". The funding supports a 4-year research initiative (8/1/2024 - 5/31/2028) aimed at identifying new factors involved in the nonvesicular transport of cholesterol within...